secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-05-14T20:31:08+00:00
Accession:  0001493152-26-023122
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q1 net income $3.5M on $6.5M revenue; reiterates going concern doubt, Nasdaq appeal pending
--------------------------------------------------------------------------------

- Q1 2026 revenue $6.5M (vs $5K Q1 2025) from Trimmune license; net income $3.5M vs net loss $2.2M YoY.
- Phase 1 HCW9302 for alopecia areata enrolling; preliminary data H1 2026, full readout Q4 2026; no DLTs.
- Closed exclusive worldwide license with Beijing Trimmune for $3.5M cash plus $3.5M equity in-kind on March 16, 2026.
- Going concern doubt exists; Nasdaq hearing granted May 5, 2026 to appeal delisting due to bid price non-compliance.
- Completed $1.5M equity financing Feb 2026 with warrants at $0.6055 exercise price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226023122/0001493152-26-023122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226023122/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer